Journal Watch · Journal of Medicinal Chemistry · 2026

Mechanistic Insights into G Protein-Biased κ-Opioid Receptor Signaling Using Dual-Charged Naltrexamine Amides.

These findings provide insight into the structural mechanisms of KOR signaling bias and inform the rational design of improved KOR therapeutics.

Doering NP, Puls K, Diceglie M et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c02135PMID: 41641864Study type: research study

TL;DR

These findings provide insight into the structural mechanisms of KOR signaling bias and inform the rational design of improved KOR therapeutics.

Key findings

  • These compounds achieve their effects through interactions with residues E209<sup>ECL2</sup>, D223<sup>5.35</sup>, E297<sup>6.58</sup>, and K227<sup>5.39</sup>.
  • These findings provide insight into the structural mechanisms of KOR signaling bias and inform the rational design of improved KOR therapeutics.

What they did

In this study, we used virtual screening to develop novel dual-charged naltrexamine amide derivatives as tool compounds for investigating biased agonism at the KOR. All of the predicted ligands demonstrate low-nanomolar activity and G protein bias at both the KOR and MOR. Molecular dynamics simulations revealed a key allosteric communication involving TM4, TM5, and ICL2.

Full abstract (original)

Background: Opioids remain a cornerstone of pain management, but currently used therapeutics are associated with serious side effects. While κ-opioid receptor (KOR) agonists offer an alternative to classical μ-opioid receptor (MOR) agonists, their clinical potential is limited by severe adverse effects. G protein-biased KOR agonists are a promising strategy for developing safer analgesics.

What they did: In this study, we used virtual screening to develop novel dual-charged naltrexamine amide derivatives as tool compounds for investigating biased agonism at the KOR. All of the predicted ligands demonstrate low-nanomolar activity and G protein bias at both the KOR and MOR. Molecular dynamics simulations revealed a key allosteric communication involving TM4, TM5, and ICL2.

Results & conclusions: These compounds achieve their effects through interactions with residues E209<sup>ECL2</sup>, D223<sup>5.35</sup>, E297<sup>6.58</sup>, and K227<sup>5.39</sup>. These findings provide insight into the structural mechanisms of KOR signaling bias and inform the rational design of improved KOR therapeutics.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02135 · PubMed 41641864.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

These findings provide insight into the structural mechanisms of KOR signaling bias and inform the rational design of improved KOR therapeutics.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. In this study, we used virtual screening to develop novel dual-charged naltrexamine amide derivatives as tool compounds for investigating biased agonism at the KOR.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02135. PubMed ID: 41641864. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Doering NP, Puls K, Diceglie M et al.. Mechanistic Insights into G Protein-Biased κ-Opioid Receptor Signaling Using Dual-Charged Naltrexamine Amides.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c02135.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/mechanistic-insights-into-g-protein-biased-opioid-receptor-signaling-usi-c02135/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides